Payment overview · 2025
General Payments
$899.01
28 reported records · 9 companies
Healthcare provider profile · identity verified
Leonid Basovich, DO, DAOBFP
Allopathic & Osteopathic Physicians|Family Medicine · CITRUS HEIGHTS, CA · NPI 1285626515
Verified facts
What the public records show
CMS Open Payments records show Leonid Basovich, DO, DAOBFP received $899.01 in general payments during 2025 across 28 reported records.
Aimmune Therapeutics, Inc. accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $248.19 | 27.6% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $223.34 | 24.8% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $163.74 | 18.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $158.85 | 17.7% | 6 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $23.22 | 2.6% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $22.92 | 2.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.67 | 2.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.26 | 2.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.82 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $899.01 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $205.26 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $163.74 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $162.91 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $88.92 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $83.47 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $69.93 | 3 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $42.93 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $42.38 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
62 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 206 | 69 |
| Lisinopril | Lisinopril | 187 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 142 | 46 |
| Metformin Hcl | Metformin Hcl | 134 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 109 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 34 |
| Omeprazole | Omeprazole | 95 | 16 |
| Losartan Potassium | Losartan Potassium | 91 | 30 |
| Ibuprofen | Ibuprofen | 88 | 30 |
| Clonidine Hcl | Clonidine Hcl | 77 | 22 |
| Tramadol Hcl | Tramadol Hcl | 72 | 16 |
| Gabapentin | Gabapentin | 67 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 18 |
| Eliquis | Apixaban | 62 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 16 |
| Meloxicam | Meloxicam | 49 | 11 |
| Clonazepam | Clonazepam | 47 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 43 | 14 |
| Buprenorphine Hcl | Buprenorphine Hcl | 42 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 42 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Allopurinol | Allopurinol | 37 | 12 |
| Carvedilol | Carvedilol | 37 | 14 |
| Sucralfate | Sucralfate | 37 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 36 | 13 |
| Simvastatin | Simvastatin | 36 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | 12 |
| Atenolol | Atenolol | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Prednisone | Prednisone | 28 | 12 |
| Glipizide | Glipizide | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | 12 |
| Furosemide | Furosemide | 24 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $899.01 · 28 records | Aimmune Therapeutics, Inc. | APTIMA, BREZTRI, CREON, Cologuard Collection Kit, ELIQUIS, LINZESS, MOUNJARO, NURTEC ODT, The Cologuard Plus Collection Kit, VOWST, XIFAXAN, ZENPEP, ZEPBOUND, ZORYVE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error